Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.33 |
| ▸ | F11 | P03951 | 6/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748673 | 0.79 | HDAC6 (0.33) | HDAC6EGFRIGF1RSRCFLT4 | |
| SCHEMBL31748342 | 0.77 | KEAP1 (0.41) | F11KLKB1EGFRIGF1RSRC | |
| SCHEMBL31748668 | 0.77 | DGAT1 (0.33) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL31748486 | 0.74 | DGAT1 (0.33) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL31748662 | 0.72 | DGAT1 (0.38) | F11KLKB1EGFRIGF1RSRC | |
| SCHEMBL31748492 | 0.71 | DGAT1 (0.35) | KLKB1EGFRIGF1RSRCFLT4 | |
| SCHEMBL31748528 | 0.70 | PRKAB2 (0.38) | HDAC6 | |
| SCHEMBL17548085 | 0.66 | KDM4E (0.32) | — | |
| SCHEMBL23540273 | 0.65 | HDAC6 (0.56) | HDAC6 | |
| SCHEMBL30959382 | 0.65 | DGAT1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | HDAC6 674/4885F11 3955/4885KLKB1 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.